Omeros lays plans for $115M stock offering

Seattle-based Omeros has blueprinted plans for an IPO to raise $115 million. Omeros is betting that its experimental therapies for inflammation and CNS disorders can snag investors' dollars to complete a late-stage study of its lead drug. Omeros has burned through $72 million since it started in 1994 and had $27 million on hand as of last September. The Seattle Times notes that the filing comes after a rough year for IPOs, with more filings withdrawn last year than completed.

- see this release
- read the report from the Seattle Times

Related Articles:
Omeros to buy Nura in cash/stock deal. Report
Omeros gets new funding. Report

Suggested Articles

Eli Lilly is combining the oncology team at Lilly Research Laboratories with Loxo Oncology and putting a trio of Loxo execs at the helm.

The failure of SAGE-217 to beat placebo wiped more than 50% off Sage’s share price as investors digested the implications of the data.

The data tee Aurinia up to file for FDA approval next year and go on to address a major unmet medical need.